Financial reports
10-K
2023 FY
Annual report
22 Mar 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
10-Q
2023 Q2
Quarterly report
31 Jul 23
10-Q
2023 Q1
Quarterly report
12 May 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
23 May 22
NT 10-Q
Notice of late quarterly filing
16 May 22
10-K
2021 FY
Annual report
11 Apr 22
Current reports
8-K
Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials
24 Aug 23
8-K
Entry into a Material Definitive Agreement
12 Jun 23
8-K
Changes in Registrant's Certifying Accountant
7 Mar 23
8-K
Bioxytran Receives Approval to Initiate Trials with ProLectin-I
6 Feb 23
8-K
Bioxytran Establishes Indian Subsidiary in Preparation of Commercialization
14 Dec 22
8-K
Bioxytran Receives Approval to Optimize Dosage in COVID-19 Patients
8 Dec 22
8-K
Bioxytran Releases Positive Top-line Results from Phase 2 Trial of Galectin Antagonist on COVID-19 Patients in medRxiv Pre-print
16 Nov 22
8-K
Entry into a Material Definitive Agreement
14 Nov 22
8-K
Entry into a Material Definitive Agreement
16 Aug 22
8-K
Other Events
1 Aug 22
Registration and prospectus
424B4
Prospectus supplement with pricing info
2 Oct 23
S-1/A
IPO registration (amended)
26 Sep 23
S-1
IPO registration
19 Sep 23
424B4
Prospectus supplement with pricing info
14 Aug 23
S-1/A
IPO registration (amended)
8 Aug 23
S-1/A
IPO registration (amended)
2 Aug 23
S-1/A
IPO registration (amended)
12 Jul 23
S-1/A
IPO registration (amended)
7 Jul 23
S-1/A
IPO registration (amended)
30 Jun 23
S-1
IPO registration
16 Jun 23
Proxies
DEF 14C
Information statement
15 Oct 18
PRE 14C
Preliminary information
3 Oct 18
SC 14F1
Statement regarding change in majority of directors
3 Oct 18
DEF 14C
Information statement
13 Aug 18
PRE 14C
Preliminary information
1 Aug 18
DEF 14C
Information statement
31 Mar 15
PRE 14C
Preliminary information
19 Mar 15
DEF 14C
Information statement
3 Mar 15
DEF 14C
Information statement
3 Mar 15
PRER14C
Preliminary revised information
26 Feb 15
Other
EFFECT
Notice of effectiveness
2 Oct 23
CORRESP
Correspondence with SEC
28 Sep 23
UPLOAD
Letter from SEC
26 Sep 23
CORRESP
Correspondence with SEC
20 Sep 23
EFFECT
Notice of effectiveness
15 Aug 23
CORRESP
Correspondence with SEC
10 Aug 23
UPLOAD
Letter from SEC
12 Jul 23
UPLOAD
Letter from SEC
6 Jul 23
UPLOAD
Letter from SEC
29 Jun 23
EFFECT
Notice of effectiveness
26 Jul 21